University of Washington

Omeros Corporation

Seattle Children's Hospital

Suzie H Pun

Wayne Richard Gombotz

Christopher Mount

Tae Hee Kim

Nataly Kacherovsky

Benjamin W Dulken

Michael C Jensen

Nathan J White

Meilyn Sylvestre

Leslie Chan

Jamie M Bergen

Yilong Cheng

Philip J Horner

Drew L Sellers

Emmeline Cheng

Ian Cardle

Chris Saxby

Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human T-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered T cells are isolated utilizing a two-stage MTX selection that employs increasing concentrations of MTX.

Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection

Provided herein are compositions comprising aptamers that specifically bind monocytes and/or macrophage and methods for their use. These aptamer compositions can be used in methods for isolating and/or enriching monocytes and/or macrophages or depleting cell populations of monocytes and/or macrophages. Further provided are methods of using the aptamers or cell populations generated using them in the methods disclosed herein for therapies and/or drug delivery.

Monocyte and macrophage binding aptamers and their application

Membrane-lytic block copolymers, micellar assemblies, pharmaceutical compositions, and related methods are described.

Membrane-lytic block copolymers

A biocompatible polymer to which a plurality of clot-modulating peptides (CMPs) are bound. The polymer comprises repeating units of hydrophilic monomers and display monomers to which the CMPs are bound. For example, the CMPs can be fibrin binding peptides (FBPs) that enhance clot formation by cross-linking that occurs within and between fibers by the plurality of fibrin-binding peptides during fibrin polymerization. The polymers of the invention can be used to modulate clotting in a variety of ways via multivalent display of fibrin-binding peptides and other clot-binding and clot-modulating moieties on polymer or co-polymer backbones. In addition to clot-modulating moieties, imaging agents and therapeutic agents can be conjugated to the polymers to facilitate imaging of blood flow and thrombosis, and for treatment of clotting-related disorders.

Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders

This disclosure is directed to mixed micelle compositions for administration of e.g., therapeutic agents or imaging agents to a subject.

Mixed micelles

Transport peptides, alone or attached to a cargo moiety, are capable of targeted axonal import into the spinal cord and other structures of the central nervous system. The transport peptides can be used to deliver therapeutic agents and other molecules of interest from the periphery to the central nervous system, providing a means to detect, treat or prevent neurodegenerative diseases, stroke, chronic pain and other conditions via minimally invasive techniques of administration.

Retrograde transport peptide and use of same for delivery to central nervous system

Growing community of inventors

Seattle, WA, United States of America

Suzie H Pun